Diagnosis and Management of Chronic Daily Headache

ABSTRACT

Chronic daily headache (CDH) is a descriptive term that encompasses multiple headache diagnoses and affects ~4% of the general adult population. Chronic daily headache results in significant pain and suffering with substantial impact on quality of life, and enormous economic costs to society. Although most patients with primary CDH suffer from chronic migraine or chronic tension-type headache, other primary and secondary headache disorders can also manifest as a CDH syndrome. For CDH management to succeed, secondary headaches need to be ruled out with proper investigations when judged necessary. If the diagnosis of primary CDH is established, diagnosis of the specific CDH subtype is imperative to institute appropriate treatment. The diagnosis and management of distinct CDH entities, chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua, are the primary forms of CDH and the emphasis of this review. Although, strictly speaking, medication overuse headache is a secondary form of CDH, it is also highlighted in this review given its frequent association with primary CDH.

KEYWORDS

Chronic - daily - headache - migraine - hemicrania

REFERENCES

• 1 Scher A I, Stewart W F, Liberman J, Lipton R B. Prevalence of frequent headache in a population sample.  Headache. 1998;  38(7) 497-506
• 2 Lu S R, Fuh J L, Chen W T, Juang K D, Wang S J. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors.  Cephalalgia. 2001;  21(10) 980-986
• 3 Wang S J, Fuh J L, Lu S R et al.. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up.  Neurology. 2000;  54(2) 314-319
• 4 Stewart W F, Ricci J A, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce.  JAMA. 2003;  290(18) 2443-2454
• 5 Lipton R B, Stewart W F, Scher A I. Epidemiology and economic impact of migraine.  Curr Med Res Opin. 2001;  17(Suppl 1) s4-s12
• 6 Scher A I, Midgette L A, Lipton R B. Risk factors for headache chronification.  Headache. 2008;  48(1) 16-25
• 7 Scher A I, Stewart W F, Buse D, Krantz D S, Lipton R B. Major life changes before and after the onset of chronic daily headache: a population-based study.  Cephalalgia. 2008;  28(8) 868-876
• 8 Scher A I, Stewart W F, Lipton R B. Caffeine as a risk factor for chronic daily headache: a population-based study.  Neurology. 2004;  63(11) 2022-2027
• 9 Scher A I, Stewart W F, Ricci J A, Lipton R B. Factors associated with the onset and remission of chronic daily headache in a population-based study.  Pain. 2003;  106(1-2) 81-89
• 10 Castillo J, Muñoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population.  Headache. 1999;  39(3) 190-196
• 11 Guitera V, Muñoz P, Castillo J, Pascual J. Quality of life in chronic daily headache: a study in a general population.  Neurology. 2002;  58(7) 1062-1065
• 12 D'Amico D, Usai S, Grazzi L et al.. Quality of life and disability in primary chronic daily headaches.  Neurol Sci. 2003;  24(Suppl 2) S97-S100
• 13 Harwood R H, Sayer A A, Hirschfeld M. Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios.  Bull World Health Organ. 2004;  82(4) 251-258
• 14 Munakata J, Hazard E, Serrano D et al.. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.  Headache. 2009;  49(4) 498-508
• 15 Katsarava Z, Schneeweiss S, Kurth T et al.. Incidence and predictors for chronicity of headache in patients with episodic migraine.  Neurology. 2004;  62(5) 788-790
• 15a Lipton R B. Tracing transformation: chronic migration classification, progression, and epidemiology.  Neurology. 2009;  72(5 Suppl) S3-S7
• 16 Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients.  Neurology. 2001;  57(1) 132-134
• 17 Schwedt T J, Dodick D W. Advanced neuroimaging of migraine.  Lancet Neurol. 2009;  8(6) 560-568
• 18 Welch K M, Nagesh V, Aurora S K, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?.  Headache. 2001;  41(7) 629-637
• 19 Kruit M C, Launer L J, Overbosch J, van Buchem M A, Ferrari M D. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study.  Cephalalgia. 2009;  29(3) 351-359
• 20 Schmitz N, Admiraal-Behloul F, Arkink E B et al.. Attack frequency and disease duration as indicators for brain damage in migraine.  Headache. 2008;  48(7) 1044-1055
• 21 Valfrè W, Rainero I, Bergui M, Pinessi L. Voxel-based morphometry reveals gray matter abnormalities in migraine.  Headache. 2008;  48(1) 109-117
• 22 Rocca M A, Ceccarelli A, Falini A et al.. Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study.  Stroke. 2006;  37(7) 1765-1770
• 23 Schmitz N, Arkink E B, Mulder M et al.. Frontal lobe structure and executive function in migraine patients.  Neurosci Lett. 2008;  440(2) 92-96
• 24 Granziera C, DaSilva A F, Snyder J, Tuch D S, Hadjikhani N. Anatomical alterations of the visual motion processing network in migraine with and without aura.  PLoS Med. 2006;  3(10) e402
• 25 Ashkenazi A, Mushtaq A, Yang I, Oshinsky M L. Ictal and interictal phonophobia in migraine-a quantitative controlled study.  Cephalalgia. 2009;  29(10) 1042-1048
• 26 Olesen J, Bousser M G, Diener H C Headache Classification Committee et al. New appendix criteria open for a broader concept of chronic migraine.  Cephalalgia. 2006;  26(6) 742-746
• 27 Silberstein S D, Lipton R B, Dodick D W Topiramate Chronic Migraine Study Group et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.  Headache. 2007;  47(2) 170-180
• 28 Diener H C, Bussone G, Van Oene J C, Lahaye M, Schwalen S, Goadsby P J. TOPMAT-MIG-201(TOP-CHROME) Study Group . Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.  Cephalalgia. 2007;  27(7) 814-823
• 29 Spira P J, Beran R G. Australian Gabapentin Chronic Daily Headache Group . Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study.  Neurology. 2003;  61(12) 1753-1759
• 30 Saper J R, Lake III A E, Cantrell D T, Winner P K, White J R. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.  Headache. 2002;  42(6) 470-482
• 31 Saper J R, Silberstein S D, Lake III A E, Winters M E. Double-blind trial of fluoxetine: chronic daily headache and migraine.  Headache. 1994;  34(9) 497-502
• 32 Krymchantowski A V, Silva M T, Barbosa J S, Alves L A. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study.  Headache. 2002;  42(6) 510-514
• 33 Rapoport A M, Sheftell F D, Tepper S J, Bigal M. Levetiracetam in the preventive treatment of transformed migraine.  Curr Ther Res. 2005;  66 212-221
• 34 Mathew N T, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study.  Headache. 1991;  31(2) 71-74
• 35 Freitag F G, Diamond S, Diamond M L, Urban G J. Divalproex in the long-term treatment of chronic daily headache.  Headache. 2001;  41(3) 271-278
• 36 Naumann M, So Y, Argoff C E Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology. 2008;  70(19) 1707-1714
• 37 Spengos K, Theleritis C, Paparrigopoulos T. Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach?.  Headache. 2008;  48(2) 284-286
• 38 Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine.  Headache. 2008;  48(9) 1337-1342
• 39 Ciancarelli I, Tozzi-Ciancarelli M G, Spacca G, Di Massimo C, Carolei A. Relationship between biofeedback and oxidative stress in patients with chronic migraine.  Cephalalgia. 2007;  27(10) 1136-1141
• 40 Martin P R, Forsyth M R, Reece J. Cognitive-behavioral therapy versus temporal pulse amplitude biofeedback training for recurrent headache.  Behav Ther. 2007;  38(4) 350-363
• 41 Lockett D M, Campbell J F. The effects of aerobic exercise on migraine.  Headache. 1992;  32(1) 50-54
• 42 Marcus D A, Scharff L, Mercer S, Turk D C. Nonpharmacological treatment for migraine: incremental utility of physical therapy with relaxation and thermal biofeedback.  Cephalalgia. 1998;  18(5) 266-272, discussion 242
• 43 Seok J I, Cho H I, Chung C S. From transformed migraine to episodic migraine: reversion factors.  Headache. 2006;  46(7) 1186-1190
• 44 Schwartz B S, Stewart W F, Simon D, Lipton R B. Epidemiology of tension-type headache.  JAMA. 1998;  279(5) 381-383
• 45 Lavados P M, Tenhamm E. Epidemiology of tension-type headache in Santiago, Chile: a prevalence study.  Cephalalgia. 1998;  18(8) 552-558
• 46 Russell M B, Levi N, Saltyte-Benth J, Fenger K. Tension-type headache in adolescents and adults: a population based study of 33,764 twins.  Eur J Epidemiol. 2006;  21(2) 153-160
• 47 Bendtsen L, Jensen R. Tension-type headache: the most common, but also the most neglected, headache disorder.  Curr Opin Neurol. 2006;  19(3) 305-309
• 48 Juang K D, Wang S J, Fuh J L, Lu S R, Su T P. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes.  Headache. 2000;  40(10) 818-823
• 49 Fumal A S. Chronic tension-type headache. In: Goadsby PJ, Dodick DW Chronic Daily Headache for Clinicians. 1st Ed. Hamilton, Ontario; BC Decker Inc 2005: 57-64
• 50 Mathew N T. Tension-type headache.  Curr Neurol Neurosci Rep. 2006;  6(2) 100-105
• 51 Bendtsen L, Jensen R, Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headache.  Arch Neurol. 1996;  53(4) 373-376
• 52 Buchgreitz L, Egsgaard L L, Jensen R, Arendt-Nielsen L, Bendtsen L. Abnormal pain processing in chronic tension-type headache: a high-density EEG brain mapping study.  Brain. 2008;  131(Pt 12) 3232-3238
• 53 Pielsticker A, Haag G, Zaudig M, Lautenbacher S. Impairment of pain inhibition in chronic tension-type headache.  Pain. 2005;  118(1-2) 215-223
• 54 Schmidt-Wilcke T, Leinisch E, Straube A et al.. Gray matter decrease in patients with chronic tension type headache.  Neurology. 2005;  65(9) 1483-1486
• 55 Headache Classification Subcommittee of the International Headache Society . The International Classification of Headache Disorders, 2nd Edition.  Cephalalgia. 2004;  24(Suppl 1) 1-160
• 56 Jensen R, Becker W J. Symptomatology of chronic tension-type headaches. In: Olesen J, Ramadan NM, Tfelt-Hansen P, Welch KMA The Headaches. 3rd ed. Philadelphia; Lippincott Williams and Wilkins 2006: 693-699
• 57 Bigal M E, Lipton R B. Tension-type headache: classification and diagnosis.  Curr Pain Headache Rep. 2005;  9(6) 423-429
• 58 Lenaerts M E. Pharmacoprophylaxis of tension-type headache.  Curr Pain Headache Rep. 2005;  9(6) 442-447
• 59 Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache.  J Neurol Neurosurg Psychiatry. 1996;  61(3) 285-290
• 60 Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache.  Neurology. 2004;  62(10) 1706-1711
• 61 Garza I, Swanson J W. Prophylaxis of migraine.  Neuropsychiatr Dis Treat. 2006;  2(3) 281-291
• 62 Holroyd K A, O'Donnell F J, Stensland M, Lipchik G L, Cordingley G E, Carlson B W. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial.  JAMA. 2001;  285(17) 2208-2215
• 63 Cohen G L. Protriptyline, chronic tension-type headaches, and weight loss in women.  Headache. 1997;  37(7) 433-436
• 64 Lampl C, Marecek S, May A, Bendtsen L. A prospective, open-label, long-term study of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache.  Cephalalgia. 2006;  26(10) 1203-1208
• 65 Yurekli V A, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu H R, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups.  J Headache Pain. 2008;  9(1) 37-41
• 66 Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study.  Headache. 1992;  32(10) 509-513
• 67 Murros K, Kataja M, Hedman C et al.. Modified-release formulation of tizanidine in chronic tension-type headache.  Headache. 2000;  40(8) 633-637
• 68 Langemark M, Olesen J. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial.  Headache. 1994;  34(1) 20-24
• 69 Holroyd K A, Labus J S, O'Donnell F J, Cordingley G E. Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation.  Headache. 2003;  43(9) 999-1004
• 70 Adelman L C, Adelman J U, Von Seggern R, Mannix L K. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting.  Headache. 2000;  40(7) 572-580
• 71 Mitsikostas D D, Gatzonis S, Thomas A, Ilias A. Buspirone vs amitriptyline in the treatment of chronic tension-type headache.  Acta Neurol Scand. 1997;  96(4) 247-251
• 72 Schulte-Mattler W J, Martinez-Castrillo J C. Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations.  Eur J Neurol. 2006;  13(Suppl 1) 51-54
• 73 Walker Z, Walker R W, Robertson M M, Stansfeld S. Antidepressant treatment of chronic tension-type headache: a comparison between fluoxetine and desipramine.  Headache. 1998;  38(7) 523-528
• 74 Söderberg E, Carlsson J, Stener-Victorin E. Chronic tension-type headache treated with acupuncture, physical training and relaxation training. Between-group differences.  Cephalalgia. 2006;  26(11) 1320-1329
• 75 Melis P M, Rooimans W, Spierings E L, Hoogduin C A. Treatment of chronic tension-type headache with hypnotherapy: a single-blind time controlled study.  Headache. 1991;  31(10) 686-689
• 76 Quinn C, Chandler C, Moraska A. Massage therapy and frequency of chronic tension headaches.  Am J Public Health. 2002;  92(10) 1657-1661
• 77 Bronfort G, Nilsson N, Haas M et al.. Non-invasive physical treatments for chronic/recurrent headache.  Cochrane Database Syst Rev. 2004;  (3) CD001878
• 78 Bigal M E, Rapoport A M, Sheftell F D, Tepper S J, Lipton R B. Transformed migraine and medication overuse in a tertiary headache centre—clinical characteristics and treatment outcomes.  Cephalalgia. 2004;  24(6) 483-490
• 79 Mathew N T, Kurman R, Perez F. Drug induced refractory headache—clinical features and management.  Headache. 1990;  30(10) 634-638
• 80 Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications.  Headache. 2006;  46(Suppl 4) S202-S211
• 81 Kavuk I, Katsarava Z, Selekler M et al.. Clinical features and therapy of medication overuse headache.  Eur J Med Res. 2004;  9(12) 565-569
• 82 Smith T R, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management.  Drugs. 2004;  64(22) 2503-2514
• 83 Bigal M E, Serrano D, Buse D, Scher A, Stewart W F, Lipton R B. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.  Headache. 2008;  48(8) 1157-1168
• 84 Bigal M E, Lipton R B. Excessive acute migraine medication use and migraine progression.  Neurology. 2008;  71(22) 1821-1828
• 85 Diener H C, Limmroth V. Medication-overuse headache: a worldwide problem.  Lancet Neurol. 2004;  3(8) 475-483
• 86 Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headaches de novo?.  Headache. 1988;  28(1) 61-62
• 87 Ayzenberg I, Obermann M, Nyhuis P et al.. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures.  Cephalalgia. 2006;  26(9) 1106-1114
• 88 Fumal A, Laureys S, Di Clemente L et al.. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine.  Brain. 2006;  129(Pt 2) 543-550
• 89 Boes C J, Black D F, Dodick D W. Pathophysiology and management of transformed migraine and medication overuse headache.  Semin Neurol. 2006;  26(2) 232-241
• 90 Saper J R, Hamel R L, Lake III A E. Medication overuse headache (MOH) is a biobehavioural disorder.  Cephalalgia. 2005;  25(7) 545-546
• 91 Fuh J L, Wang S J, Lu S R, Juang K D. Does medication overuse headache represent a behavior of dependence?.  Pain. 2005;  119(1-3) 49-55
• 92 Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness.  Cephalalgia. 2006;  26(10) 1192-1198
• 93 Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs.  Cephalalgia. 2006;  26(9) 1097-1105
• 94 Obermann M, Katsarava Z. Management of medication-overuse headache.  Expert Rev Neurother. 2007;  7(9) 1145-1155
• 95 Bøe M G, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study.  Neurology. 2007;  69(1) 26-31
• 96 Diener H C. How to treat medication-overuse headache: prednisolone or no prednisolone?.  Neurology. 2007;  69(1) 14-15
• 97 Mathew N T. Amelioration of ergotamine withdrawal symptoms with naproxen.  Headache. 1987;  27(3) 130-133
• 98 Krymchantowski A V, Barbosa J S. Prednisone as initial treatment of analgesic-induced daily headache.  Cephalalgia. 2000;  20(2) 107-113
• 99 Lu S R, Fuh J L, Juang K D, Wang S J. Repetitive intravenous prochlorperazine treatment of patients with refractory chronic daily headache.  Headache. 2000;  40(9) 724-729
• 100 Silberstein S D, Schulman E A, Hopkins M M. Repetitive intravenous DHE in the treatment of refractory headache.  Headache. 1990;  30(6) 334-339
• 101 Ford R G, Ford K T. Continuous intravenous dihydroergotamine in the treatment of intractable headache.  Headache. 1997;  37(3) 129-136
• 102 Schwartz T H, Karpitskiy V V, Sohn R S. Intravenous valproate sodium in the treatment of daily headache.  Headache. 2002;  42(6) 519-522
• 103 Katsarava Z, Jensen R. Medication-overuse headache: where are we now?.  Curr Opin Neurol. 2007;  20(3) 326-330
• 104 Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener H C, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study.  Cephalalgia. 2005;  25(1) 12-15
• 105 Garza I, Swanson J W. Answers to frequently asked questions about migraine.  Mayo Clin Proc. 2006;  81(10) 1387-1391, quiz 1392
• 106 Rozen T D. New daily persistent headache.  Curr Pain Headache Rep. 2003;  7(3) 218-223
• 107 Vanast W J. New daily persistent headaches definition of a benign syndrome.  Headache. 1986;  26 317-320 (Abstract)
• 108 Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan.  Cephalalgia. 2004;  24(11) 955-959
• 109 Li D, Rozen T D. The clinical characteristics of new daily persistent headache.  Cephalalgia. 2002;  22(1) 66-69
• 110 Bigal M E, Sheftell F D, Rapoport A M, Lipton R B, Tepper S J. Chronic daily headache in a tertiary care population: correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria for chronic daily headache.  Cephalalgia. 2002;  22(6) 432-438
• 111 Diaz-Mitoma F, Vanast W J, Tyrrell D L. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches.  Lancet. 1987;  1(8530) 411-415
• 112 Hamada T, Ohshima K, Ide Y, Sakato S, Takamori M. A case of new daily persistent headache with elevated antibodies to Epstein-Barr virus.  Jpn J Med. 1991;  30(2) 161-163
• 113 Meineri P, Torre E, Rota E, Grasso E. New daily persistent headache: clinical and serological characteristics in a retrospective study.  Neurol Sci. 2004;  25(Suppl 3) S281-S282
• 114 Santoni J R, Santoni-Williams C J. Headache and painful lymphadenopathy in extracranial or systemic infection: etiology of new daily persistent headaches.  Intern Med. 1993;  32(7) 530-532
• 115 Rozen T D. New daily persistent headache. In: Goadsby PJ, Dodick DW Chronic Daily Headache for Clinicians. 1st Ed. Hamilton, Ontario; BC Decker Inc. 2005: 209-215
• 116 Goadsby P J, Boes C. New daily persistent headache.  J Neurol Neurosurg Psychiatry. 2002;  72(Suppl 2) ii6-ii9
• 117 Rossi P, Faroni J, Tassorelli C, Nappi G. Diagnostic delay and suboptimal management in a referral population with hemicrania continua.  Headache. 2009;  49(2) 227-234
• 118 Peres M F, Silberstein S D, Nahmias S et al.. Hemicrania continua is not that rare.  Neurology. 2001;  57(6) 948-951
• 119 Dodick D. Hemicrania continua: diagnostic criteria and nosologic status.  Cephalalgia. 2001;  21(9) 869-872
• 120 Matharu M S, Cohen A S, McGonigle D J, Ward N, Frackowiak R S, Goadsby P J. Posterior hypothalamic and brainstem activation in hemicrania continua.  Headache. 2004;  44(8) 747-761
• 121 Irimia P, Arbizu J, Prieto E, Fernández-Torrón R, Martínez-Vila E. Activation of the brainstem but not of the hypothalamus in hemicrania continua without autonomic symptoms.  Cephalalgia. 2009;  29(9) 974-979
• 122 Matharu M S, Boes C J, Goadsby P J. Management of trigeminal autonomic cephalgias and hemicrania continua.  Drugs. 2003;  63(16) 1637-1677
• 123 Marmura M J, Silberstein S D, Gupta M. Hemicrania continua: who responds to indomethacin?.  Cephalalgia. 2009;  29(3) 300-307
• 124 Bigal M E, Tepper S J, Rapoport A M, Sheftell F D. Hemicrania continua: comparison between two different classification systems.  Cephalalgia. 2002;  22(3) 242-245
• 125 Eross E J, Swanson J W, Dodick D W. Hemicrania continua: an indomethacin-responsive case with an underlying malignant etiology.  Headache. 2002;  42(6) 527-529
• 126 Antonaci F, Sjaastad O. Hemicrania continua: a possible symptomatic case, due to mesenchymal tumor.  Funct Neurol. 1992;  7(6) 471-474
• 127 Valença M M, Andrade-Valença L P, da Silva W F, Dodick D W. Hemicrania continua secondary to an ipsilateral brainstem lesion.  Headache. 2007;  47(3) 438-441
• 128 Rogalewski A, Evers S. Symptomatic hemicrania continua after internal carotid artery dissection.  Headache. 2005;  45(2) 167-169
• 129 Peres M F, Zukerman E, Porto P P, Brandt R A. Headaches and pineal cyst: a (more than) coincidental relationship?.  Headache. 2004;  44(9) 929-930
• 130 Levy M J, Matharu M S, Meeran K, Powell M, Goadsby P J. The clinical characteristics of headache in patients with pituitary tumours.  Brain. 2005;  128(Pt 8) 1921-1930
• 131 Pareja J, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Interval between indomethacin administration and response.  Headache. 1996;  36(1) 20-23
• 132 Pareja J A, Caminero A B, Franco E, Casado J L, Pascual J, Sánchez del Río M. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua.  Cephalalgia. 2001;  21(9) 906-910
• 133 Rozen T D. Melatonin responsive hemicrania continua.  Headache. 2006;  46(7) 1203-1204
• 134 Peres M F, Silberstein S D. Hemicrania continua responds to cyclooxygenase-2 inhibitors.  Headache. 2002;  42(6) 530-531
• 135 Schwedt T J, Dodick D W, Hentz J, Trentman T L, Zimmerman R S. Occipital nerve stimulation for chronic headache—long-term safety and efficacy.  Cephalalgia. 2007;  27(2) 153-157
• 136 Camarda C, Camarda R, Monastero R. Chronic paroxysmal hemicrania and hemicrania continua responding to topiramate: two case reports.  Clin Neurol Neurosurg. 2008;  110(1) 88-91
• 137 Burns B, Watkins L, Goadsby P J. Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study.  Lancet Neurol. 2008;  7(11) 1001-1012
• 138 Garza I, Cutrer F. Pain relief and persistence of dysantonomic features in a patient with hemicrania continua responsive to botulinum toxin type A.  Cephalalgia. 2009;  , June 10 (Epub ahead of print)